
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a promising company with a strong innovative pipeline targeting critical signaling pathways in cancer, such as RAF/MEK and FAK inhibition. With a Phase 3 trial for their KRAS G12D PDAC treatment underway in China, the company could potentially gain a market advantage in this area. The favorable initial data for VS-7375, along with the potential for Avutometinib to become a new standard of care, points to a positive outlook for the company's future success and potential financial growth.
Bears say
Verastem is a company with a limited addressable market in NSCLC due to the prevalence of the KRAS G12D mutation and the safety profiles of their potential treatment options not standing out compared to competitors. Their PDAC analysis provided some reassurance, but overall the readout will focus more on safety rather than early efficacy in a small sample patient count. In addition to their lead program for low-grade serous ovarian cancer, the company has several other notable programs in development, but their success is uncertain and launch may not occur until 2025.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares